Ruxolitinib
Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
| Trivial name | INCB018424 |
| Catalog Number | S1378 |
| Molecular Formula | C17H18N6 |
| CAS# | 941678-49-5 |
| Inchi | InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1 |
| Inchi Key | HFNKQEVNSGCOJV-OAHLLOKOSA-N |
| SMILES | C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
| Size | 5mg |
| Supplier Page | http://www.selleckchem.com/products/INCB18424.html |
| Additional Information | https://file.selleck.cn/downloads/struct/s1378-ruxolitinib-incb018424-chemical-structure.png |